Proceedings of the National Academy of Sciences,
Год журнала:
2022,
Номер
120(1)
Опубликована: Дек. 27, 2022
Nanoparticles
(NPs)
are
confronted
with
limited
and
disappointing
delivery
efficiency
in
tumors
clinically.
The
tumor
extracellular
matrix
(ECM),
whose
physical
traits
have
recently
been
recognized
as
new
hallmarks
of
cancer,
forms
a
main
steric
obstacle
for
NP
diffusion,
yet
the
role
ECM
diffusion
remains
largely
unexplored.
Here,
we
characterized
properties
clinical
gastric
samples
observed
distribution
NPs
decellularized
tissues.
We
also
performed
molecular
dynamics
simulations
vitro
hydrogel
experiments
through
single-particle
tracking
to
investigate
mechanism
understand
influence
on
both
individually
collectively.
Furthermore,
developed
an
estimation
model
evaluation
scores
comprehensive
analyses
data.
Thus,
beyond
finding
that
loose
soft
aligned
structure
contribute
efficient
now
systemic
predict
based
provide
critical
guidance
personalized
diagnosis
treatment.
The
malignant
tumor
is
a
multi-etiological,
systemic
and
complex
disease
characterized
by
uncontrolled
cell
proliferation
distant
metastasis.
Anticancer
treatments
including
adjuvant
therapies
targeted
are
effective
in
eliminating
cancer
cells
but
limited
number
of
patients.
Increasing
evidence
suggests
that
the
extracellular
matrix
(ECM)
plays
an
important
role
development
through
changes
macromolecule
components,
degradation
enzymes
stiffness.
These
variations
under
control
cellular
components
tissue
via
aberrant
activation
signaling
pathways,
interaction
ECM
to
multiple
surface
receptors,
mechanical
impact.
Additionally,
shaped
regulates
immune
which
results
suppressive
microenvironment
hinders
efficacy
immunotherapies.
Thus,
acts
as
barrier
protect
from
supports
progression.
Nevertheless,
profound
regulatory
network
remodeling
hampers
design
individualized
antitumor
treatment.
Here,
we
elaborate
on
composition
ECM,
discuss
specific
mechanisms
remodeling.
Precisely,
highlight
impact
development,
proliferation,
anoikis,
metastasis,
angiogenesis,
lymphangiogenesis,
escape.
Finally,
emphasize
"normalization"
potential
strategy
for
anti-malignant
Nature Communications,
Год журнала:
2022,
Номер
13(1)
Опубликована: Авг. 6, 2022
The
tumour
stroma,
and
in
particular
the
extracellular
matrix
(ECM),
is
a
salient
feature
of
solid
tumours
that
plays
crucial
role
shaping
their
progression.
Many
desmoplastic
including
breast
cancer
involve
significant
accumulation
type
I
collagen.
However,
recently
it
has
become
clear
precise
distribution
organisation
molecules
such
as
collagen
equally
important
abundance.
Cancer-associated
fibroblasts
(CAFs)
coexist
within
tissues
play
both
pro-
anti-tumourigenic
roles
through
remodelling
ECM.
Here,
using
temporal
proteomic
profiling
decellularized
tumours,
we
interrogate
evolving
matrisome
during
We
identify
4
key
matrisomal
clusters,
pinpoint
XII
critical
component
regulates
organisation.
Through
combining
our
proteomics
with
single-cell
transcriptomics,
genetic
manipulation
models,
show
how
CAF-secreted
alters
to
create
pro-invasive
microenvironment
supporting
metastatic
dissemination.
Finally,
patient
cohorts
may
represent
an
indicator
patients
at
high
risk
relapse.
Nature,
Год журнала:
2022,
Номер
610(7931), С. 366 - 372
Опубликована: Окт. 5, 2022
Abstract
Pancreatic
ductal
adenocarcinoma
(PDAC)
is
a
highly
desmoplastic,
aggressive
cancer
that
frequently
progresses
and
spreads
by
metastasis
to
the
liver
1
.
Cancer-associated
fibroblasts,
extracellular
matrix
type
I
collagen
(Col
I)
support
2,3
or
restrain
progression
of
PDAC
may
impede
blood
supply
nutrient
availability
4
The
dichotomous
role
stroma
in
PDAC,
mechanisms
through
which
it
influences
patient
survival
enables
desmoplastic
cancers
escape
limitation,
remain
poorly
understood.
Here
we
show
matrix-metalloprotease-cleaved
Col
(cCol
intact
(iCol
exert
opposing
effects
on
bioenergetics,
macropinocytosis,
tumour
growth
metastasis.
Whereas
cCol
activates
discoidin
domain
receptor
(DDR1)–NF-κB–p62–NRF2
signalling
promote
iCol
triggers
degradation
DDR1
restrains
PDAC.
Patients
whose
tumours
are
enriched
for
express
low
levels
NRF2
have
improved
median
compared
those
high
I,
NRF2.
Inhibition
DDR1-stimulated
expression
NF-κB
mitochondrial
biogenesis
blocks
tumorigenesis
wild-type
mice,
but
not
mice
MMP-resistant
I.
diverse
patients
mediated
I–DDR1–NF-κB–NRF2
pathway,
targeting
components
this
pathway
could
provide
therapeutic
opportunities.
Advanced Materials,
Год журнала:
2023,
Номер
unknown
Опубликована: Авг. 10, 2023
Rapid
advancements
in
materials
science
and
nanotechnology,
intertwined
with
oncology,
have
positioned
photothermal
therapy
(PTT)
as
a
promising
noninvasive
treatment
strategy
for
cancer.
The
breast's
superficial
anatomical
location
aesthetic
significance
render
breast
cancer
particularly
pertinent
candidate
the
clinical
application
of
PTT
following
melanoma.
This
review
comprehensively
explores
research
conducted
on
various
types
nanoparticles
employed
elaborates
their
specific
roles
mechanisms
action.
integration
existing
therapies
is
scrutinized,
underscoring
its
potential
synergistic
outcomes.
Additionally,
underlying
consequential
modifications
to
tumor
microenvironment
after
are
elaborated
from
medical
perspective.
Future
directions
suggested,
an
emphasis
development
integrative
platforms
that
combine
multiple
therapeutic
approaches
optimization
nanoparticle
synthesis
enhanced
efficacy.
goal
push
boundaries
toward
comprehensive,
clinically
applicable
Cancers,
Год журнала:
2023,
Номер
15(1), С. 321 - 321
Опубликована: Янв. 3, 2023
Due
to
the
absence
of
hormone
receptor
(both
estrogen
receptors
and
progesterone
receptors)
along
with
human
epidermal
growth
factor
2
(HER-2)
amplification,
treatment
triple-negative
breast
cancer
(TNBC)
cannot
benefit
from
endocrine
or
anti-HER-2
therapy.
For
a
long
time,
chemotherapy
was
only
systemic
for
TNBC.
lack
effective
options,
prognosis
TNBC
is
extremely
poor.
The
successful
application
immune
checkpoint
inhibitors
(ICIs)
launched
era
immunotherapy
in
However,
current
findings
show
modest
efficacy
programmed
cell
death-
(ligand)
1
(PD-(L)1)
monotherapy
small
proportion
patients
can
this
approach.
Based
on
basic
principles
characteristics
tumor
microenvironment
(TIME)
TNBC,
combination
therapy
expected
further
enhance
expand
beneficiary
population
patients.
Given
diversity
drugs
that
be
combined,
it
important
select
biomarkers
identify
target
population.
Moreover,
side
effects
associated
multiple
should
also
considered.
